| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 60.82 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Medulloblastoma has poor outcome due also to adverse events caused by the treatment [1]. An improved anti-tumor strategy is needed to enhance patient survival rate. REST is a transcription factor overexpressed in medulloblastoma cells and it’s associated with the formation of this brain tumor and the low survival rate, suggesting an oncogenic role [2][3].
Description
Keywords
Medulloblastoma Anti-tumor strategy
Citation
Monteiro, R., Baiula, M., Santos, M., & Spampinato, S. (2021). FOXO3-REST Axis: a Therapeutic Target for Medulloblastoma? 15th YES Meeting
Publisher
Wolters Kluwer Health